Bria J Rice1, Matthew R Buras2, Heidi E Kosiorek2, Kyle E Coppola3, Shailja B Amin4, Patricia M Verona5, Curtiss B Cook6, Nina J Karlin3,4. 1. Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA. 2. Department of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA. 3. Mayo Clinic Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA. 4. Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA. 5. Department of Information Technology, Mayo Clinic, Scottsdale, AZ 85259, USA. 6. Division of Endocrinology, Mayo Clinic, Scottsdale, AZ 85259, USA.
Abstract
AIM: We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control. PATIENTS & METHODS: Patients with lymphoma with and without diabetes (2005-2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan-Meier method. Hemoglobin A1c (HbA1c) and glucose levels during the year after cancer diagnosis were compared by mixed models. RESULTS: For patients with diabetes, mean HbA1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53-76%) versus 58% (95% CI: 46-71%) (p = 0.42). CONCLUSION: Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.
AIM: We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control. PATIENTS & METHODS: Patients with lymphoma with and without diabetes (2005-2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan-Meier method. Hemoglobin A1c (HbA1c) and glucose levels during the year after cancer diagnosis were compared by mixed models. RESULTS: For patients with diabetes, mean HbA1c during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53-76%) versus 58% (95% CI: 46-71%) (p = 0.42). CONCLUSION: Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.